Inhibitors of glycoprotein processing act at an early stage of myogenesis.

The glycoprotein processing inhibitors bromoconduritol and N-methyl-1-deoxynojirimycin inhibit myoblast fusion and differentiation, suggesting the critical involvement of one or more glycoproteins in the control of skeletal myogenesis. In the present study we have examined the effect of inhibitors of glycoprotein processing on the expression of the muscle-specific regulatory factor myogenin. Glucosidase inhibitors, but not the mannosidase inhibitor 1-deoxymannojirimycin, inhibited the accumulation of myogenin mRNA in myoblasts, and immunoblotting confirmed that this was reflected in reduced accumulation of myogenin protein. The results indicate that the glycoprotein(s) critically involved in the control of myoblast differentiation act at an early stage in this process by modulating expression of the myogenic regulatory factor myogenin.